Stay updated on Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe study record for a phase I/II trial of carboplatin, nab-paclitaxel, and pembrolizumab in advanced non-small cell lung cancer is available, including its design, eligibility criteria, outcomes, and results. It also indicates that the trial was terminated after being fully accrued and is no longer recruiting.SummaryDifference68%

- Check18 days agoChange DetectedThe ClinicalTrials.gov footer now shows revision v3.8.0 instead of v3.7.2. The page still displays a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2; the page still displays a 403 error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1; the page remains a 403 Forbidden error rather than a clinical trial record.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the study details with a minimal error page and a site footer.SummaryDifference21%

Stay in the know with updates to Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.